Method of manufacturing of 7-ethyl-10-hydroxycamptothecin

Details Method of manufacturing of 7-ethyl-10-hydroxycamptothecin Method of manufacturing of 7-ethyl-10-hydroxycamptothecin

2009-05-07

2011-10-18

Aulakh, Charanjit (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S047000

Reexamination Certificate

active

08039626

ABSTRACT:
The method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I characterized in that 7-ethyl-1,2,6,7-tetrahydrocampotothecin of formula IV is oxidized with an oxidizing agent selected from the group comprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in a solvent formed by a saturated aliphatic monocarboxylic add containing 1 to 3 carbon atoms, and in the presence of water.

REFERENCES:
patent: 3894029 (1975-07-01), Winterfeldt et al.
patent: 4031098 (1977-06-01), Sugasawa
patent: 4339276 (1982-07-01), Yokoyama et al.
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4513138 (1985-04-01), Miyasaka et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 4914205 (1990-04-01), Sawada et al.
patent: 5061800 (1991-10-01), Yaegashi et al.
patent: 5491237 (1996-02-01), Fang et al.
patent: 5602141 (1997-02-01), Bedeschi et al.
patent: 5734056 (1998-03-01), Burk et al.
patent: 5843954 (1998-12-01), Yaegashi et al.
patent: 6235907 (2001-05-01), Henegar et al.
patent: 6310210 (2001-10-01), Ogawa et al.
patent: 6403569 (2002-06-01), Achterrath
patent: 6444820 (2002-09-01), Henegar et al.
patent: 6743918 (2004-06-01), Yaegashi et al.
patent: 6794370 (2004-09-01), Achterrath
patent: 7126000 (2006-10-01), Ogawa et al.
patent: 7151179 (2006-12-01), Lin et al.
patent: 7544801 (2009-06-01), Dobrovolny
patent: 2004/0235878 (2004-11-01), Lin et al.
patent: 2005/0272757 (2005-12-01), Naidu
patent: 2006/0199961 (2006-09-01), Dobrovolny
patent: 74770 (1983-03-01), None
patent: 88642 (1983-09-01), None
patent: 51289 (1986-04-01), None
patent: 74256 (1986-11-01), None
patent: 154584 (1988-02-01), None
patent: 154583 (1988-09-01), None
patent: WO96/31513 (1996-10-01), None
patent: WO2004/100897 (2004-11-01), None
patent: WO2005/019223 (2005-03-01), None
patent: WO2005/058910 (2005-06-01), None
Li, Yu-yan, et al., “Improving Synthetic Method of Irinotecan,” Zhongguo Yaowu Huaxue Zazhi, 11(4), pp. 238-240, 2001. (English Abstract attached.).
Akimoto, et al., “Photodegradation reactions of CPT-II, a derivative of camptotheicn. I: chemical structure of main degradation products in an aqueous solutin,”Drug Stability, vol. 1(2), pp. 118-122, 1996.
Armand, Jean-Pierre et al., “Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies,”Anti-Cancer Drugs, vol. 10 (Suppl. 1), pp. S5-S12, 1999.
Ducreux, M. et al., “Phase 1/11 study of escalating dose of CPT-11 in combination wit LV5FU2 (“De Gramont” regimen) every 2 weeks in the treatment of colorectoal cancer (CRC) after 5-FU failure,” Abstract 823,Proc. of Amer. Soc. Clin. Oncol., vol. 16, p. 234a, 1997.
Nishiyama, M., “Irinotecan (CPT-11) in the treatment of gastrointestinal cancers,”Japanese J. Chemotherapy, vol. 46(8), pp. 292-296, 1998.
Pavillard et al., “Combination of Irinotecan (CPT-11) and 5-Fluorouracil with an analysis of cellular determinants of drug activity,”Biochemical Pharmacology, vol. 56, pp. 1315-1322, 1998.
Seitz, L. et al., “CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer,”European J. Cancer, vol. 32A (Suppl 3), pp. S24-S31, 1996.
Sawada et al., “Chemical Modification of an Antitumor Camptothecin: Snythesis and Antitumor Activity of 7-C-Substituted Camptothecins,”Chemical&Pharmaceutical Bulletin, vol. 39(10), pp. 2574-2580, 1991.
Sawada et al., “Snythesis and Antitumor Activity of A-Ring or E-Lactone Modified Water-Soluble Prodrugs of 20(S)-Camptothecin, Including Development of Irinotecan Hydrochloride Trihydrate,”Current Pharmaceutical Design, vol. 1(1), pp. 113-132, 1995.
Sawada et al., “Snythesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7, 10-Disubstituted Camptothecins,”Chemical&Pharmaceutical Bulletin, vol. 39(12), pp. 3183-3188, 1991.
Sawada et al., “Snythesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin,”Chemical&Pharmaceutical Bulletin, vol. 39(6), pp. 1446-1454, 1991.
Seitz, J.F. et al., “Phase I/II study of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) afte 5-FU failure,”Annals of Oncology, vol. 9 (Suppl 2), p. 68, 1998.
Vanhoefer, U. et al., “Phase I study of a weekly schedule of Irinotecan (CPT-11), high-dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer: Final results,” Abstract 779, Proc. of Amer.Soc. Clin. Oncol., vol. 17, p. 202a, 1998.
Vanhoefer, U. et al., “Phase I study of a weekly schedule of Irinotecan (CPT-11) in combination with high-dose folinic acid and 5-fluorouracil as first line chemotherapy in patients with advanced colorectal cancer,” Abstract 97, Proc. of Amer.Soc. Clin. Oncol., vol. 16, p. 272a, 1997.
Wood, et al., “An Efficient Conversion of Camptothecin to 10-Hydroxycamptothecin,” The Journal ofOrganic Chemistry, vol. 60(17), pp. 5739-5740, 1995.
Yaegashi et al,. “Snythesis and Antitumor Activity of 20(S)-Camptothecin Derivatives, A-Ring—Substituted 7-Ethylcamptothecins and their E-Ring-Modified Water-Soluble Derivatives,”Chemical&Pharmaceutical Bulletin, vol. 42(12), pp. 2518-2525, 1994.

Affiliated with

Also associated with

Rating

Method of manufacturing of 7-ethyl-10-hydroxycamptothecin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of manufacturing of 7-ethyl-10-hydroxycamptothecin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of manufacturing of 7-ethyl-10-hydroxycamptothecin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277784